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Results: Ninety-seven patients (median age 50 years, range 23 to 89) were
included. All received external beam radiotherapy (50 Gy in 5 weeks) with
concurrent weekly cisplatin (40 mg/m2) followed by high dose rate brachy-
therapy. During the 5 weeks of chemoradiation the median fall in lympho-
cyte count was 1.28 109/l. Those with a fall in lymphocyte count greater
than the median had a statistically signiﬁcant improved DFS (74.5% vs 40% at
5 years, P¼ 0.001), LRFS (74.5% vs 46% at 5 years, P¼ 0.01), and OS (75.5% vs
49% at 5 years, P¼ 0.02). In the multivariate analysis a fall in lymphocyte
count was associated with a signiﬁcant improvement in DFS (HR 0.35; 95% CI
0.18e0.64; P¼ 0.0002), LRFS (HR 0.33; 95% CI 0.16e0.6; P¼ 0.0002) and OS
(HR 0.30; 95% CI 0.14e0.57; P¼ 0.0001), respectively.
Conclusions: Fall in lymphocyte count during chemoradiation for cervical
carcinoma is an independent predictor for treatment outcome.
36 Induction TPF Combined with Concurrent Cisplatin Chemoradio-
therapy for Stage IV Head and Neck Squamous Cell Cancer
R.J. Prestwich, D. C¸. €Oks€uz, K. Dyker, C. Coyle, M. S¸en
Department of Clinical Oncology, St James's Institute of Oncology,
Leeds, UK
Aim: The feasibility and efﬁcacy of combining induction taxane-based
chemotherapy with concurrent cisplatin chemoradiotherapy for locally
advanced head and neck squamous cell carcinoma (HNSCC) has been
uncertain.
Methods: Between March 2006 and February 2010, 66 patients with non-
metastatic stage IV HNSCCwere treated in a single institutionwith three cycles
of inductionTPF (docetaxel75mg/m2, cisplatin75mg/m2, 5-FU750mg/m2days
2e5) followed by radical radiotherapy with concurrent cisplatin 100 mg/m2.
Results:Median agewas 54 (range 33e69). Median follow-up was 21 months
(range 4e55). During TPF grade 3 toxicity occurred in 18 (27%), dose modi-
ﬁcations in 10 (15%), delays in three (5%) and unplanned admissions in six
(9%) patients; a clinical tumour response was documented in 60 (91%)
patients. Median time from the ﬁnal cycle of TPF to commencing radio-
therapy was 22 days. Sixty-two (94%) patients received radical radiotherapy,
and all completed treatment with no delays 3 days. One, two and three
cycles of concurrent cisplatin were delivered to 18 (29%), 38 (61%) and three
(5%) patients, respectively. Ninety-two per cent of patients received enteral
feeding; median weight loss during treatment was 7%. Forty-two (68%)
patients had unplanned admissions with no on-treatment deaths. Three
unrelated deaths occurred post-treatment. At 1 year post-treatment 21% of
patients without disease progression remained gastrostomy dependent. 50/
58 (86%) assessable patients achieved a complete response post-treatment.
One and 2 year progression free survival (PFS), cause-speciﬁc survival (CSS)
and overall survival (OS) were 88%, 92%, 86% and 80%, 85%, 80%, respectively.
Conclusion: The combination of induction TPF with concurrent cisplatin
chemoradiotherapy is feasible with encouraging efﬁcacy.
37 Correlation of HPV Status to Treatment Outcomes Post Radiotherapy
in Tonsillar Carcinoma: a UK Regional Centre Experience
R. Pearson *, R. Brown y, M. Robinson z, C. Kelly *, S. Chatterjee x
*Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS
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zDepartment of Pathology, Newcastle upon Tyne Hospitals NHS Trust,
Newcastle upon Tyne, UK
x Tata Medical Centre, Kolkata, India
Aim: We performed a single centre, retrospective audit to evaluate radio-
therapy treatment outcomes for HPV positive and negative patients with
tonsillar carcinoma.
Methods: Case notes of 45 patients treated at the Newcastle upon Tyne
Hospitals NHS Trust, between January 2000 and December 2003 with
tonsillar cancers were analysed. Data were collected for patient demo-
graphics, risk factors, treatment details and outcomes. HPV status was
determined using a combination of p16 immunohistochemistry and in situ
hybridisation.
Results: Median follow-up was 40.37 months (range 2.5e106.5); 62.5% of
patients were HPV positive. Seven-six per cent of this group were male,
median age 49 years (range 40e71), 92% were stage III/IV and 60% were
smokers. This compared with 80% male in the HPV negative group,
median age 60 years (range 15e76), 86.7% stage III/IV, 73.3% smokers.
Eighty per cent of the HPV postitive group underwent surgery followed by
adjuvant radiotherapy. Twenty per cent had primary radiotherapy 
chemotherapy compared to 73.3% and 20% in the HPV negative group.
After 3 years 60% of HPV positive patients were alive; 16% had local
recurrences; 8% died from other primary cancers. At 5 years, 48% were still
alive. In the HPV negative group 40% were alive at 3 years; 30% locally
recurred, one was treated with surgery; 13.3% died with other primaries.
At 5 years, 33% were alive.
Conclusions: HPV positive patients were younger and had weaker association
with smoking compared to HPV negative cases. HPV negative patients had
worse local control and overall survival on a stage by stage comparison. This
raises the question about the rationality of certain de-escalation strategies
advocated for HPV positive oropharyngeal cancer cases. On the other hand,
dose escalation in locally advanced patients could be explored within clinical
trials and prospective stratiﬁed HPV data analysed further to ascertain the
two groups in order to identify subgroups that could beneﬁt from such
approaches.
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Introduction: This paper will review progress on two aspects of the
Birmingham BNCT project. Firstly on evaluation of the effects of high and low
LET radiations when delivered simultaneously, and secondly on attempts to
optimise delivery of the boron carrier compound BPA through pharmacoki-
netic studies.
Methods: Simultaneous or non-simultaneous irradiations of V79 cells with
alpha-particle and X-ray irradiations were performed. Alpha doses of 2 and
2.5 Gy were chosen and the impact on survival when delivered separately or
simultaneously with variable doses of X-rays was evaluated. The pharma-
cokinetics of the delivery of a new formulation of BPA (BPA-mannitol) are
being investigated in brain tumour patients through a study with 2 2
design featuring intravenous and intracarotid artery infusion of BPA, with or
without a mannitol bolus.
Results: On the combined effect of low and high LET radiations, a synergistic
effect was observed when alpha and X-ray doses are delivered simulta-
neously. The effect is only present at the 2.5 Gy alpha dose and is a very
substantial effect on both the shape of the survival curve and the level of cell
killing. This indicates that the alpha component may have the effect of
inhibiting the repair of damage from the low LET radiation dose delivered
simultaneously. On the pharmacokinetics of BPA, data on the ﬁrst three
cohorts indicate that bioavailability of BPA in brain ECF is increased
substantially through the addition of a mannitol bolus, as well as by the use
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of intracarotid artery route of infusion. In both cases, for some patients the
levels after infusion approach those seen in blood, whereas the ECF levels for
intravenous infusion without mannitol are typically less than 10% of the
blood values.
Conclusion: The magnitude of the synergistic effect between high and low
LET radiations delivered simultaneously has been quantiﬁed. Tumour-
selective uptake of boron in a new formulation of BPA has been conﬁrmed.
39 Immunological Proﬁling of T Cell Functional Changes during Prostate
and Pelvic Nodal Radiotherapy
J. Staffurth
Cardiff University, Cardiff, UK
Background: Cancer vaccines are new treatments that have entered the early
clinical trial phase as single agents and in combination with conventional
therapies. For such novel treatment combinations it is important to charac-
terise the immune status of patients receiving conventional therapies alone.
We carried out sequential multiparameter immunological monitoring of
prostate cancer (PCa) patients with locally advanced disease undergoing
hormone therapy (HT) and radiotherapy (RT).
Methods: Blood samples from 12 patients, receiving 3e6 months of neo-
adjuvant HT prior to radical RT, which consisted of a single phase deliv-
ering 55 Gy in 20 fractions to the prostate and 44 Gy in 20 fractions to the
pelvic nodes were collected at baseline (0e4 weeks after initiation of ADT),
RT0 (day 0 of RT), RT1 (after one fraction of RT), RT20 (during week 4 of RT)
and post-RT4 (4 weeks post RT). Mononuclear cells and plasma for
immunological assays were isolated by Histopaque density gradient
centrifugation.
Results: Longitudinal follow-up of patients revealed several signiﬁcant
immunological changes during RT. Both the numbers of T cells in peripheral
blood and the ability of these T cells to undergo proliferation in vitro were
impaired. T cell proliferationwas completely rescued by exogenous IL-2 post-
RT. There was signiﬁcantly more loss of naive and early memory T cells
compared to more differentiated T cells in the blood of patients during RT.
Furthermore, memory T cell responses to common viral antigens, measured
by IFN-g production, were little affected by RT and anti-tumour CD4+ and
CD8+ T cell responses became detectable after RT.
Conclusions: RT triggers complex immunological changes in PCa patients
resulting in a preferential impairment of naive compared to memory T cells.
The appearance of tumour-speciﬁc T cell activity suggests a potential
immunological element in tumour-responses. These results can inform the
scheduling of radio-immunotherapy in PCa.
40 Implementation of Volumetric Arc Therapy (VMAT) for Head and
Neck Cancer
G. Lamb, S. Smith, M. Glegg
Beatson West of Scotland Cancer Centre (BWoSCC), Department of Clinical
Physics and Bio-Engineering, Gartnavel General Hospital, Glasgow, UK
Aim: The Varian VMAT solution, RapidArc, was retrospectively installed on
two of the 11 linacs at the BWoSCC in May 2010. The ﬁrst VMAT treatment
was delivered within 4 weeks of installation. This study compares initial
planned dose distributions for conventional intensity modulated radio-
therapy (IMRT) and VMAT, and also considers the dosimetric effects of
weight loss for head and neck cancer.
Method: Ten patients with ﬂoor of mouth PTVs who were previously treated
with IMRT were retrospectively planned for single and double arc VMAT
plans. The patients received 68 Gy and 61.2 Gy to primary and nodal PTVs,
respectively, in 34 fractions. Calculated dose to the PTVs and organs at risk
(OAR) were compared. V3Gy, V5Gy, V10Gy, V20Gy and total plan monitor units
were also compared. Following implementation, CBCT scans were obtained
weekly for 15 patients. The CBCTs were used to recalculate the treatment
plans and assess the impact of weight loss on central nervous system (CNS)
dose.
Results: The mean conformity index (CI)¼ 0.93 and 0.96 and the mean sigma
index (SI)¼ 4.2 and 3.8 for IMRT and double arc VMAT plans, respectively.
The OAR dose was comparable and there was a 60% reduction in MU. The
V3Gy and V5Gy were increased by an average of 30% and 10%, respectively, for
VMAT plans. There was no signiﬁcant difference in V10Gy and V20Gy between
both planning techniques. The assessment of weekly CBCTs showed that
weight loss increased the CNS maximum dose by up to 9%.
Conclusions: VMAT for head and neck cancer can be implemented smoothly
and quickly into a large, busy cancer centre. Double arc planning gives
comparable OAR and improved PTV doses. VMAT plans give a reduction in
MU but have a dose bathing effect at V3Gy and V5Gy. An evaluation of weight
loss must be performed during treatment for VMAT patients.
41 Imaged Guided Intensity Modulated Radiotherapy for Head and Neck
Cancers
S. Manolopoulos, P. Massey, J. Bode, J. Cashmore, A. Hartley,
K. Natarajan, P. Sanghera
Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital,
University Hospital Birmingham NHS Trust, Birmingham, UK
Background: Delivery time can be prolonged with ‘step and shoot’ intensity-
modulated radiotherapy (IMRT) for head and neck cancers. Although inter-
fraction displacement has helped to deﬁne reduced PTV margins in many
departments, estimation of intrafraction displacement is more difﬁcult to
evaluate and has often not been taken into account.
Methods: Twenty-six patients were treated with IMRT using an Elekta
Synergy linear accelerator. Immobilisation was provided by a thermoplastic
shell. A margin of 5 mmwas used to grow the PTV from the CTV. Cone beam
computed tomography (CBCT) imaging was performed and compared to the
planning CT to calculate the positional errors in setting-up the patient.
Translational corrections (couch shifts) were applied if the discrepancy
between CBCT and planning CT was outside local protocol tolerance levels of
2 mm. It was not possible to correct for rotations. The van Herk formula was
used to calculate the PTV margin.
Results: Twenty-six patients have been studied to date. The mean inter-
fraction shifts derived from 246 CBCT images were 0.36 0.08, 0.38 0.11
and 0.29 0.11 mm in the medialelateral, superioreinferior and ante-
rioreposterior dimensions, respectively, with 70% of all shifts within 2 mm
from the planning CT. Following couch corrections, only one patient had
post-CBCT images with more than 2 mm shifts from the planning CT. Data
will be presented on the ability to reduce PTV margins using daily online
correction.
Conclusions: Daily IGRT with online correction can be used to deliver head
and neck IMRT. Correction data vary according to the deﬁned region of
interest for the CBCT co-registration with the planning CT images and is
operator dependent. Based on RBE of 1.1 for KV X-ray imaging, the estimated
additional biological effective dose of daily CBCT delivering 1.5 mGy with
a schedule of 55 Gy in 20 fractions is 77.8 mGy3.
42 Volumetric Modulated Arc Therapy vs Intensity Modulated Radio-
therapy for Three Dose Level Prostate Treatments
C.J. Boylan, C.G. Rowbottom
North Western Medical Physics, The Christie NHS Foundation Trust,
Manchester, UK
Aims: The aim of this study was to compare single arc VMAT against ﬁxed
ﬁeld IMRT for multiple dose-level prostate treatments.
Methods: Ten patients previously treated with ﬁve ﬁeld IMRT were re-
planned using the Philips SmartArc planning module. The prescription was
57 Gy mean dose to the prostate in 19 fractions, with dose constraints on
three planning target volumes (PTVs). The VMAT plans consisted of a single
360 arc with a spacing of 4 between each control point. Comparisons were
made between the IMRT and VMAT plans by analysing dose volume char-
acteristics. Plans were delivered on the linear accelerator to assess the
delivery time, and veriﬁcation was performed using the Scandidos Delta4.
Results: For the target volumes, the VMAT plans provided better coverage to
PTV1 (a two-tailed t-test gives P<< 0.05). PTV2 and PTV3 coverage was
similar between IMRT and VMAT (P> 0.5 in both cases). The volume of
rectum receiving a high dose (V54Gy) was reduced with VMAT (P<< 0.05),
whereas the intermediate to low dose volumes were similar. VMAT plans
required an average of 494 MU whereas IMRT required 509 MU (P> 0.5).
Planning time with SmartArc was approximately 2 h (including contouring
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